Short Interest in IPSEN (OTCMKTS:IPSEY) Drops By 92.8%

IPSEN (OTCMKTS:IPSEY) was the recipient of a significant drop in short interest in May. As of May 29th, there was short interest totaling 37 shares, a drop of 92.8% from the May 14th total of 514 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average daily volume of 2,616 shares, the days-to-cover ratio is presently 0.0 days.

Analyst Ratings Changes

A number of brokerages have recently issued reports on IPSEY. HC Wainwright initiated coverage on IPSEN in a research note on Friday. They set a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a report on Thursday, May 14th. Finally, Zacks Research raised shares of IPSEN to a “hold” rating in a research report on Friday, May 29th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold”.

IPSEN Stock Performance

OTCMKTS:IPSEY opened at $46.75 on Wednesday. The stock’s 50 day moving average price is $47.94 and its two-hundred day moving average price is $42.84. IPSEN has a 12-month low of $28.66 and a 12-month high of $51.10.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).